XML 55 R40.htm IDEA: XBRL DOCUMENT
v3.24.1

SUBSEQUENT EVENTS (Details) $ in Thousands |  |  |  | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Jan. 01, 2024 shares | Jan. 01, 2023 shares | Jun. 15, 2022 shares | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Mar. 08, 2024 USD ($) site
Subsequent Event [Line Items] |  |  |  |  |  |  |
Research and development | $ |  |  |  |  | $ 6,798 | $ 5,677 |
Forecast | Clinical Research Organization |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Research and development | $ |  |  |  | $ 700 |  |  |
Subsequent Event | Clinical Research Organization |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Amount to be paid to Clinical Research Organization | $ |  |  |  |  |  |  | $ 500
Number of planned sites to carrying out the clinical study | site |  |  |  |  |  |  | 5
2022 Equity Plan |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Number of annual increase of shares authorized (in shares) | shares |  |  | 3,800,000 |  |  |  |
Percentage of total number of outstanding shares of all classes of common stock (as a percent) |  |  | 5.00% |  |  |  |
Number of additional shares authorized for issuance (in shares) | shares |  | 400,487 |  |  |  |  |
2022 Equity Plan | Subsequent Event |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Percentage of total number of outstanding shares of all classes of common stock (as a percent) | 5.00% |  |  |  |  |  |
Number of additional shares authorized for issuance (in shares) | shares | 1,316,452 |  |  |  |  |  |

X
- Definition Research And Development, Number Of Clinical Study Sites + References No definition available. + Details
Name: | beat_ResearchAndDevelopmentNumberOfClinicalStudySites
Namespace Prefix: | beat_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan + References No definition available. + Details
Name: | beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
Namespace Prefix: | beat_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of additional shares authorized for issuance under share-based payment arrangement. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beat_ClinicalResearchOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=beat_A2022EquityPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |